Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
Volume 4, Issue 2, June 2020, Pages 47-63
Dysregulation of glutathione synthesis in liver disease
Volume 4, Issue 2, June 2020, Pages 64-73
Vitamins and non-alcoholic fatty liver disease: A molecular insight
Volume 5, Issue 2, June 2021, Pages 62-71
Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
Volume 4, Issue 4, December 2020, Pages 168-172
Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease
Volume 4, Issue 1, March 2020, Pages 15-22
Bile acid receptors and signaling crosstalk in the liver, gut and brain
Volume 5, Issue 3, September 2021, Pages 105-118
Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
Volume 6, Issue 2, June 2022, Pages 72-83
Intestinal barrier function and metabolic/liver diseases
Volume 4, Issue 2, June 2020, Pages 81-87
Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
Volume 4, Issue 4, December 2020, Pages 173-179
Functional roles of CCL5/RANTES in liver disease
Volume 4, Issue 1, March 2020, Pages 28-34
Clinical perspectives of isoniazid-induced liver injury
Volume 5, Issue 2, June 2021, Pages 45-52
Hepatocellular carcinoma recurrence: Predictors and management
Volume 7, Issue 4, December 2023, Pages 321-332
Lipid and energy metabolism in Wilson disease
Volume 4, Issue 1, March 2020, Pages 5-14
Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function
Volume 5, Issue 3, September 2021, Pages 171-180
Golgi protein 73, hepatocellular carcinoma and other types of cancers
Volume 4, Issue 4, December 2020, Pages 161-167
Mitigation of cholestasis-associated hepatic and renal injury by edaravone treatment: Evaluation of its effects on oxidative stress and mitochondrial function
Volume 5, Issue 3, September 2021, Pages 181-193
Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease
Volume 5, Issue 3, September 2021, Pages 119-141
Nuclear receptors and non-alcoholic fatty liver disease: An update
Volume 4, Issue 2, June 2020, Pages 88-93
Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets
Volume 5, Issue 3, September 2021, Pages 142-150
Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do
Volume 8, Issue 2, June 2024, Pages 83-90
MiR-22 as a metabolic silencer and liver tumor suppressor
Volume 4, Issue 2, June 2020, Pages 74-80
A fluorescence imaging based-assay to monitor mitophagy in cultured hepatocytes and mouse liver
Volume 5, Issue 1, March 2021, Pages 16-20
The clinical implication of gamma-glutamyl transpeptidase in COVID-19
Volume 5, Issue 4, December 2021, Pages 209-216
Mesenchymal stem cells therapy for acute liver failure: Recent advances and future perspectives
Volume 5, Issue 2, June 2021, Pages 53-61
The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Volume 4, Issue 1, March 2020, Pages 23-27